Vaxcyte PCVX
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
Vaxcyte (PCVX) Core Market Data and Business Metrics
Latest Closing Price
$33.69Price-Earnings Ratio
-8.87Total Outstanding Shares
128.76 Million SharesDividend
No dividendSIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
825 Industrial Road, Ste. 300, San Carlos, CA, 94070
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 1,257,210 Shares | 10.03 | 3/14/2025 | 12,609,286 Shares |
| 1,288,545 Shares | 9.57 | 2/28/2025 | 12,330,962 Shares |
| 876,755 Shares | 15.21 | 2/14/2025 | 13,334,612 Shares |
| 1,298,843 Shares | 10.42 | 1/31/2025 | 13,532,683 Shares |
| 1,095,601 Shares | 13.22 | 1/15/2025 | 14,486,757 Shares |
| 1,211,462 Shares | 11.82 | 12/31/2024 | 14,322,764 Shares |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities | $-452.63 Million |
| Net Cash Flow From Investing Activities | $-2.01 Billion |
| Net Cash Flow, Continuing | $-9.79 Million |
| Net Cash Flow From Financing Activities, Continuing | $2.45 Billion |
| Net Cash Flow From Operating Activities, Continuing | $-452.63 Million |
| Net Cash Flow | $-9.36 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Available To Common Stockholders, Basic | $-463.93 Million |
| Income/Loss From Continuing Operations After Tax | $-463.93 Million |
| Research and Development | $476.64 Million |
| Other Operating Expenses | $85.90 Million |
| Income/Loss From Continuing Operations Before Tax | $-463.93 Million |
| Depreciation and Amortization | $7 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $-467.98 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $-4.05 Million |
| Comprehensive Income/Loss | $-467.98 Million |
| Other Comprehensive Income/Loss Attributable To Parent | $-4.05 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Prepaid Expenses | $15.73 Million |
| Accounts Payable | $48.45 Million |
| Fixed Assets | $198.04 Million |
| Liabilities | $205.50 Million |
| Equity Attributable To Parent | $3.31 Billion |
| Other Non-current Assets | $1.53 Billion |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||